title: Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia.
abstract: The magnitude of serum lipid changes in response to hypolipidemic drugs varies considerably between individuals. These differences may be due to interactions between genetic and environmental factors that effect drug bioavailability or the capacity of the lipid-regulating enzyme and receptor targets to be affected. The apolipoprotein E (apoE) gene locus has been examined in this regard, but reports are conflicting on the effect of its variability on the response to hypolipidemic drugs. We investigated the effect of apoE polymorphism on the serum lipid response to the hepatic hydroxymethyl glutaryl coenzyme A (HMG CoA) reductase inhibitor lovastatin and the fibric acid derivative gemfibrozil. Lipoprotein changes were assessed after 12 weeks of therapy in 106 patients with primary hypercholesterolemia and combined hyperlipidemia treated with lovastastin and in 63 given gemfibrozil therapy. No significant effect of the apoE phenotypes E3/2, E3/3, or E4/3 on the heterogeneity of lipid responses to either drug was found.
authors.affiliation: Clinical Biochemistry Department, Nutrition and Dietetics Service, Hospital Clínic i Provincial, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Sanllehy
authors.forename: E
authors.initials: E
authors.lastname: Casals
authors.forename: C
authors.initials: C
authors.lastname: Rodriguez-Villar
authors.forename: D
authors.initials: D
authors.lastname: Zambón
authors.forename: J
authors.initials: J
authors.lastname: Ojuel
authors.forename: A M
authors.initials: AM
authors.lastname: Ballesta
authors.forename: E
authors.initials: E
authors.lastname: Ros
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001057:Apolipoproteins E / Q000235:genetics / Q000502:physiology*; D003627:Data Interpretation, Statistical; D004347:Drug Interactions / Q000502:physiology; D005260:Female; D015248:Gemfibrozil / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects*; D008148:Lovastatin / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011110:Polymorphism, Genetic
chemical_list: D000924:Anticholesteremic Agents; D001057:Apolipoproteins E; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D008148:Lovastatin; D015248:Gemfibrozil